Members of the epidermal growth factor receptor family (EGFR/ ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy 1 . Critical for activation is the formation of an asymmetric dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other 2 . The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs 3-5). Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a 25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 1. We show that signalling by EGFR molecules that contain constitutively active kinase domains still requires formation of the asymmetric dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.
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Before activation, the EGFR kinase domain is in an autoinhibited conformation that resembles that of inactive cyclin-dependent kinases (CDKs) and the Src family kinases 2, 6 . Conversion to the active form requires interactions between the distal surface of the C lobe of one kinase domain and the amino-terminal lobe (N lobe) of the other in the asymmetric activating dimer 2 . This conformational change resembles closely the activation switch induced in CDKs by cyclins 7 , even though the C lobe of the EGFR kinase domain is structurally unrelated to cyclins.
If the cyclin/CDK-like asymmetric dimer is indeed critical for EGFR activation, then the modulation of this interaction might underlie naturally occurring mechanisms of EGFR regulation. We looked for protein inhibitors of EGFR that are known to function by interacting with the intracellular portions of the receptor. One such protein is MIG6 (or receptor-associated late transducer, RALT, the gene for which is also named gene 33), which is a feedback inhibitor of both EGFR and ERBB2 (refs 3 and 5). MIG6 inhibits EGFRmediated signals in mouse skin 8 , and deletion of the MIG6 gene leads to hyper-activation of EGFR 9, 10 . The N-terminal region of MIG6 is not implicated in EGFR inhibition (Fig. 1a) . The C-terminal region shows sequence similarity to only a non-catalytic region of the ACK1 tyrosine kinase (Fig. 1a) , which also binds to the EGFR cytoplasmic domain 11 . A segment within this region of MIG6 (residues 323-372) is critical for EGFR and ERBB2 binding (Fig. 1a ) 12, 13 . We determined the crystal structure of a 60-residue fragment spanning this segment (residues 315-374) bound to the EGFR kinase domain (Supplementary Information). This structure and structures of EGFR complexed to two overlapping 40-and 25-residue fragments (residues 325-364 and 340-364) define a 25-residue epitope of MIG6 that binds to the EGFR kinase domain (residues 337-361, denoted MIG6(segment 1). The structure of the 40-residue peptide complex has been determined at 2.9 Å resolution.
The EGFR kinase domain bound to MIG6(segment 1) adopts the Src/CDK-like inactive conformation, and not the active conformation normally seen in crystals of the kinase domain (Fig. 1b) 2,6 . The interface, which buries 1,800 Å 2 of surface area, involves an extended conformation of the MIG6 peptide and disparate binding elements on the kinase domain ( Fig. 1b and c ; Supplementary Information). MIG6(segment 1) lies within a shallow depression on the distal surface of the C lobe of the kinase domain, formed by helices aG and aH and the loops connecting helices aF-aG, aG-aH and aH-aI. The interactions are mainly polar, although a few hydrophobic residues from helix aH contribute to the interface.
The footprint of MIG6(segment 1) on the kinase domain overlaps the cyclin-like face of the kinase domain in the asymmetric kinase domain dimer, and so binding of MIG6 to an EGFR kinase domain will prevent it from acting as a cyclin-like activator for other kinase domains ( Fig. 1, and see later) . Residues in EGFR located at the MIG6(segment 1)-binding interface are conserved 2 , suggesting that MIG6 will also bind to other EGFR family members.
MIG6(segment 1) binds to the EGFR kinase domain with micromolar affinity. The dissociation constant for a 30-residue fluorescein-labelled MIG6 peptide (residues 334-363, spanning the entire binding epitope of segment 1) is 13.0 6 1.3 mM (Fig. 2a , and Supplementary Table 1 ). Val 924 in the C lobe of the kinase domain is located in the centre of the asymmetric kinase domain dimer interface and also participates in the interaction between the kinase domain and MIG6(segment 1) 2 (Fig. 1b, c) . A V924R mutation in the kinase domain abolishes peptide binding (Fig. 2a) . Met 346, Phe 352 and Tyr 358 in MIG6 are within the kinase/MIG6(segment 1) interface (Fig. 1c) , and mutation of any of these residues also abrogates binding (Fig. 2b) .
The EGFR kinase domain has very low activity in solution, but is activated on increasing its local concentration by tethering it to lipid vesicles, which promotes the formation of the asymmetric dimer 2 . Various MIG6 peptides that contain segment 1 inhibit the activity of the kinase domain attached to lipid vesicles, with half maximal inhibitory concentration (IC 50 ) values of ,10 mM (Fig. 2c) . A 25-residue peptide (residues 340-364) that lacks 3 residues in the N-terminal portion of MIG6(segment 1), is much less potent (Fig. 2c , and Supplementary Information). Peptides that contain mutations that disrupt the binding interface (M346A, F352A and Y358A) do not inhibit kinase activity markedly (Fig. 2c ). An EGFR kinase domain bearing an I682Q mutation is not stimulated by concentration at the membrane because it is unable to form the asymmetric dimer 2 . The basal activity of this mutant in solution is not inhibited by MIG6(segment 1), which has the same binding affinity for this mutation as for the wild-type kinase domain ( Fig. 2a and Supplementary Fig. 3 ). Thus, MIG6(segment 1) is only able to inhibit the kinase domain in the context of asymmetric dimer formation.
We tested the inhibition of EGFR autophosphorylation by fulllength MIG6 in a cell-based assay. Co-expression of the wild-type MIG6 with EGFR decreases the EGF-induced autophosphorylation of EGFR, whereas introduction of individual mutations in MIG6(segment 1) (M346A, F352A or Y358A) abolishes this effect (Fig. 2d) , confirming that segment 1 is important for inhibition of EGFR by full-length MIG6.
An intriguing property of MIG6 is its ability to bind more tightly to activated EGFR than to the unliganded receptor 3, 5, 12 . MIG6(segment 1) alone cannot confer this property, because the kinase residues that interact with it do not change conformation on activation 2, 6, 14 . The C terminus of MIG6(segment 1) is located within a channel leading into the kinase active site (Fig. 1b) , used by peptidic inhibitors of protein kinases that interact directly with the active sites 15, 16 . The region of MIG6 that is C-terminal to segment 1 (segment 2, Fig. 1a ) contains a region of strong homology to ACK1 (also known as TNK2) (refs 3, 5 and 11). Because MIG6 and ACK1 are both sensitive to the activation state of EGFR 3, 5, 11, 12 , there may be specific interactions between segment 2 and the activation loop and/or the N lobe of the kinase domain.
To test the role of segment 2, we produced a longer peptide (residues 336-412, MIG6(segments 1-2)), and analysed its effect on a variant of the EGFR kinase domain that contains a mutation (L834R) that renders it constitutively active in the absence of concentration on vesicles 2 . MIG6(segments 1-2) inhibits this mutant kinase domain with an IC 50 value of ,200 nM (Fig. 3a) . MIG6(segments 1-2) bearing a mutation within segment 1 (Y358A) inhibited L834R much less efficiently (IC 50 ,5 mM). MIG6(segment 1) (the 30-residue peptide) did not inhibit this mutant kinase, consistent with its dimerization-independent activity. Interestingly, MIG6(segments 1-2) seems to be much less potent in inhibiting the basal activity of the wild-type kinase domain in solution, and MIG6(segments 1-2) bearing a mutation in segment 1 (Y358A) does not show any inhibition under the same conditions (Fig. 3b) . These results suggest that segment 2 is responsible for the inhibition of the activated EGFR kinase domain, and that both segments 1 and 2 are important for the high potency of inhibition.
Could MIG6 function by binding primarily to the activated kinase in an asymmetric kinase domain dimer, and not to the cyclin-like activator kinase? The MIG6(segment 1) interaction would then be important for anchorage of MIG6 to EGFR, but not directly relevant for shutting down kinase activity. Such a role may be operative in auto-inhibition of ACK1, the kinase domain of which has a conserved segment-1-binding surface, with the MIG6 homologous segments present within the same protein (Supplementary Information). We expect, however, that the asymmetric EGFR dimer will dissociate, and that activated kinase molecules can subsequently serve as cyclin-like activators. This may facilitate the lateral propagation of EGFR activation, which can spread across the cell surface even when EGF is localized to a small region 17, 18 . The interaction between MIG6(segment 1) and the kinase domain would block further transmission of the activating signal.
To examine this potential, we co-transfected cells with two variants of EGFR. One form (EGFR(activator)) resembles ERBB3 in that it is catalytically inactive (the catalytic base, Asp 813, is mutated to Asn) but can serve as a cyclin-like activator. To promote interaction with MIG6, we introduced the L834R mutation, which destabilizes the inactive conformation, into the EGFR(activator). To prevent EGFR(activator) from assuming the 'activated' position in the asymmetric dimer, we also introduced the I682Q mutation 2 . The LETTERS second EGFR variant (EGFR(activatable)) is catalytically active, but has the V924R mutation, which prevents it from serving as an activator 2 . We tested the effects of MIG6 on EGFR phosphorylation in co-transfections with these two variants. The results show that EGFR(activator) can activate EGFR(activatable) in the presence of EGF (Fig. 4a) , consistent with our previous findings 2 . Cotransfection of MIG6 with EGFR(activator) and EGFR(activatable) suppresses this activation (Fig. 4a) . MIG6(segment 1) does not bind to the kinase domain bearing the V924R mutation, and an intact MIG6(segment 1) is required for inhibition of EGFR in cellular assays (Fig. 2) . We therefore interpret the results of the triple transfection experiment (Fig. 4a) to mean that MIG6 binds to EGFR(activator) and prevents the activation of EGFR(activatable).
Full-length EGFR bearing the activating L834R mutation is not fully phosphorylated in cells 19, 20 , suggesting that the formation of the asymmetric dimer is still required for robust autophosphorylation even when the kinase domain is rendered constitutively active. We confirmed this by introducing the V924R mutation, which prevents the kinase domain from serving as the cyclin-like activator, into EGFR with a constitutively active kinase domain (L834R/V924R). EGFR(L834R/V924R) fails to undergo autophosphorylation (Fig.  4b) , although the kinase activity of this double mutant is comparable to that of the kinase domain bearing the single activating mutation (L834R) (Supplementary Fig. 6 ). EGF-stimulated autophosphorylation is restored when this double mutant is co-transfected with the kinase-dead EGFR(activator) (Fig. 4b) . These results further underscore the importance of blockage of the asymmetric dimer interface by MIG6, because it can prevent both the activation of kinase domains and downstream signalling by activated kinase domains.
Our results demonstrate that MIG6 uses a double-headed mechanism for inhibiting EGFR, with the blockage of the asymmetric cyclin/CDK-like dimer being a particularly interesting aspect of the inhibition (Fig. 4c) . This mechanism provides direct confirmation of the critical role of the asymmetric kinase domain dimer in the activation of EGFR family receptors. In addition, our results suggest an approach for the development of a new class of inhibitors that act by binding to the cyclin-like face of the C lobe of the kinase domains of this family. This region is not conserved in other protein kinases, and so such inhibitors may enable the development of cancer therapies with a high degree of specificity towards EGFR family members.
METHODS SUMMARY
The wild-type and mutant forms of the EGFR kinase domain were expressed and purified as described before 2 . The 60-residue MIG6 peptide was expressed in bacteria as a glutathione S-transferase (GST)-fusion protein, purified and treated with the TEV protease to remove the GST-moiety. The wild-type and Y358A mutant MIG6(segments 1-2) peptides were fused to a Trp DLE leader peptide and expressed as inclusion bodies and purified as described 21 . All other MIG6 peptides were produced using solid phase synthesis. The EGFR kinase domains (wild-type and the K799E mutant) were co-crystallized with the 60-residue, 25-residue and 40-residue MIG6 peptides and the structures were solved by molecular replacement using a structure of the EGFR kinase domain adopting the Src/ CDK-like inactive conformation (PDB entry: 2GS7) as the search model. The binding affinities between the kinase domain and fluorescein-labelled MIG6 peptides were measured by monitoring the change of fluorescence anisotropy during the titration and fitting the data to a single-site binding model. Kinase assays in solution and on vesicle were performed as described before 2 . Cell-based inhibition assays were performed using Cos-7 cells co-transfected with constructs containing full-length EGFR and MIG6.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
